Val66Met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression

• Published in: Pharmacological reports 2018-02, Vol.70 (1), p.55-59
• Main Authors: Skibinska, Maria, Groszewska, Agata, Kapelski, Pawel, Rajewska-Rager, Aleksandra, Pawlak, Joanna, Dmitrzak-Weglarz, Monika, Szczepankiewicz, Aleksandra, Twarowska-Hauser, Joanna
• Format: Article
• Language: English
• Subjects: Adult; Affect; Brain-derived neurotrophic factor (BDNF); Brain-Derived Neurotrophic Factor - blood; Brain-Derived Neurotrophic Factor - genetics; Case-Control Studies; Depression; Depression - blood; Depression - diagnosis; Depression - genetics; Depression - psychology; Drug Safety and Pharmacovigilance; Female; Genetic Association Studies; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Original Article; Pharmacotherapy; Pharmacy; Phenotype; Poland; Polymorphism, Single Nucleotide; Schizophrenia; Schizophrenia - blood; Schizophrenia - diagnosis; Schizophrenia - genetics; Schizophrenic Psychology; Serum BDNF level; Val66Met functional polymorphism
• ISSN: 1734-1140; 2299-5684
• DOI: 10.1016/j.pharep.2017.08.002

•Brain-derived neurotrophic factor (BDNF) is implicated in psychiatric disorders.•Study group: schizophrenia, depression and healthy controls.•Val66Met functional polymorphism have been determined using PCR-RFLP.•Serum BDNF level was measured using ELISA.•Val66Met polymorphism is not associated with BDNF serum level in our study. Brain-derived neurotrophic factor (BDNF) influences neuron differentiation during development as well as the synaptic plasticity and neuron survival in adulthood. BDNF has been implicated in the pathogenesis of schizophrenia and depression. Val66Met polymorphism and BDNF serum level are potential biomarkers in neuropsychiatric disorders. The aim of this study was to determine the effect of BDNF gene Val66Met functional polymorphism on serum BDNF concentration in patients with schizophrenia, during depression episode and in healthy control group. 183 participants were recruited (61 patients with depressive episode, 56 females with schizophrenia, 66 healthy controls) from Polish population. Serum BDNF levels were measured using ELISA method. Val66Met polymorphism was genotyped using PCR- RFLP method. Serum BDNF levels were not associated with Val66Met polymorphism in either of the groups. A significant increase of BDNF level in schizophrenia (p = 0.0005) and depression (p = 0.026) comparing to the control group has been observed. Our results suggest that the functional Val66Met BDNF polymorphism is not associated with BDNF serum levels, which is in line with previous findings. Replication studies on larger groups are needed.